
# World Journal of *Transplantation*

World J Transplant 2017 April 24; 7(2): 103-160





Published by Baishideng Publishing Group Inc

World Journal of WJT Transplantation

### Contents

Bimonthly Volume 7 Number 2 April 24, 2017

### **REVIEW**

- 103 Role of gastroesophageal reflux disease in lung transplantation Hathorn KE, Chan WW, Lo WK
- 117 Intra-islet endothelial cell and β-cell crosstalk: Implication for islet cell transplantation Narayanan S, Loganathan G, Dhanasekaran M, Tucker W, Patel A, Subhashree V, Mokshagundam S, Hughes MG, Williams SK, Balamurugan AN

### **MINIREVIEWS**

- 129 Smoking in Renal Transplantation; Facts Beyond Myth *Aref A, Sharma A, Halawa A*
- 134 Past, present and future of kidney paired donation transplantation in India Kute VB, Patel HV, Shah PR, Modi PR, Shah VR, Rizvi SJ, Pal BC, Modi MP, Shah PS, Varyani UT, Wakhare PS, Shinde SG, Ghodela VA, Patel MH, Trivedi VB, Trivedi HL

### **META-ANALYSIS**

- 144 Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant *Kumar J, Reccia I, Kusano T, Julie BM, Sharma A, Halawa A*
- 152 Living related and living unrelated kidney transplantations: A systematic review and meta-analysis Simforoosh N, Shemshaki H, Nadjafi-Semnani M, Sotoudeh M



	Vo	<i>World Journal of Transplantation</i> lume 7 Number 2 April 24, 2017
ABOUT COVER		<i>al of Transplantation</i> , Frieder Keller, MD, epartment Innere 1, University Hospital,
AIM AND SCOPE	10.5500) is a peer-reviewed open access a practice and improve diagnostic and therape <i>WJT</i> covers topics concerning organ a injury, repair, inflammation, and aging; imm nisms, and opportunities for induction of to abdominal transplantation (kidney, liver, patherapy and islet transplantation, clinical trimmunobiology and genomics, and xenotrationclude editorial, frontier, diagnostic advantation and the set of the s	nd tissue donation and preservation; tissue nune recognition, regulation, effector mecha- lerance, thoracic transplantation (heart, lung), ncreas, islets), transplantation of tissues, cell ansplantation, experimental transplantation, unsplantation. The current columns of $WJT$ nces, therapeutics advances, field of vision, al ethics, original articles, case report, clinical
AIM AND SCOPE	World Journal of Transplantation is now indexed	in PubMed, PubMed Central.
FLYLEAF I-IV	Editorial Board	
Respon	nsible Assistant Editor: Xiang Li Responsib	le Science Editor: Fang-Fang Ji
THIS ISSUE	<u> </u>	le Science Editor: Fang-Fang Ji Editorial Office Director: Xin-Xia Song
Image: Contract of the second seco	sible Electronic Editor: Huan-Liang Wu Proofing E	0 0.5
Image: Contract of the second seco	An and the set of the	<ul> <li>COPYRIGHT</li> <li>© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial</li> </ul>



Submit a Manuscript: http://www.f6publishing.com

DOI: 10.5500/wjt.v7.i2.152

World J Transplant 2017 April 24; 7(2): 152-160

ISSN 2220-3230 (online)

META-ANALYSIS

# Living related and living unrelated kidney transplantations: A systematic review and meta-analysis

Nasser Simforoosh, Hamidreza Shemshaki, Mohammad Nadjafi-Semnani, Mehdi Sotoudeh

Nasser Simforoosh, Hamidreza Shemshaki, Mohammad Nadjafi-Semnani, Mehdi Sotoudeh, Department of Urology, Shahid Labbafi Nejad Hospital, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran 198396-3113, Iran

Author contributions: Simforoosh N, Shemshaki H, Nadjafi-Semnani M and Sotoudeh M acquisition of data, analysis and interpretation of data, drafting the article and final approval; Sotoudeh M interpretation of data, revising the article and final approval.

Conflict-of-interest statement: The authors deny any conflict of interest.

Data sharing statement: No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Nasser Simforoosh, Professor, Department of Urology, Shahid Labbafi Nejad Hospital, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, 9<sup>th</sup> Boostan Avenue, Pasdaran Avenue, Tehran 198396-3113, Iran. simforoosh@iurtc.org.ir Telephone: +98-21-22588018 Fax: +98-21-22588016

Received: November 21, 2016 Peer-review started: November 23, 2016 First decision: January 16, 2017 Revised: February 20, 2017 Accepted: April 6, 2017 Article in press: April 10, 2017 Published online: April 24, 2017

# Abstract

### AIM

To compare the outcomes between related and unrelated kidney transplantations.

### **METHODS**

Literature searches were performed following the Cochrane guidelines. We conducted a systematic review and a meta-analysis, which included 12 trials that investigated outcomes including the long-term (ten years), midterm (one to five years), and short-term (one year) graft survival rate as well as the acute rejection rate. Metaanalyses were performed using fixed and random-effects models, which included tests for publication bias and heterogeneity.

### RESULTS

No difference in graft survival rate was detected in patients who underwent living related kidney transplantations compared to unrelated (P = 0.44) transplantations after ten years. There were no significant differences between the graft survival rate in living related and unrelated kidney transplantations after a short- and midterm follow-up (P = 0.35, P = 0.46). There were no significant differences between the acute rejection rate in living related and unrelated and unrelated kidney transplantations (P = 0.06).

### **CONCLUSION**

The long, mid and short term follow-up of living related and unrelated kidney transplantation showed no significant difference in graft survival rate. Also, acute rejection rate was not significantly different between groups.

**Key words:** Transplantation; Living related; Living unrelated; Graft survival rate

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.



**Core tip:** The long, mid and short term follow-up of living related and unrelated kidney transplantation showed no significant difference in graft survival rate. Also, acute rejection rate was not significantly different between groups.

Simforoosh N, Shemshaki H, Nadjafi-Semnani M, Sotoudeh M. Living related and living unrelated kidney transplantations: A systematic review and meta-analysis. *World J Transplant* 2017; 7(2): 152-160 Available from: URL: http://www.wjgnet.com/2220-3230/full/v7/i2/152.htm DOI: http://dx.doi.org/10.5500/wjt.v7.i2.152

### INTRODUCTION

Renal failure is a disease with a high rate of morbidity and mortality. By the end of 2001, with the help of dialysis and renal transplantations, approximately 1479000 people were kept alive. This number increased to 1783000 by the end of 2004<sup>[1]</sup>. Nowadays, renal transplantation has become the optimal treatment for patients with end-stage renal disease<sup>[2]</sup>. The recipients of renal transplant had a higher quality of life and a greater survival rate in comparison to patients who underwent dialysis. Due to these results, the demand of renal transplantations has increased over time, but the gap between supply and demand has widened. Consequently, the number of patients who are on the renal transplant waiting list for deceased-donor transplantation has increased and thousands of patients have died while waiting for their renal transplantation. This has made it necessary to search for alternatives.

During the past two decades, several approaches have been adopted to increase living related organ donations, but living unrelated donors remain an underutilized source. The result of living unrelated transplantations was widely disputed. While the Brazilian<sup>[3]</sup>, Iranian<sup>[4,5]</sup>, and Egyptian<sup>[6]</sup> experiences resulted in excellent outcomes that were superior to those in cadavers and were comparable to living related-donor transplantations, there were contradictory reports in several studies<sup>[7,8]</sup>. To our knowledge, there was no systematic review and meta-analysis that evaluated outcomes in patients who underwent living related vs unrelated kidney transplantations. This systematic review and meta-analysis was designed to compare the outcomes including the long-, mid- and short-term graft survival rate, and the acute rejection rate between related and unrelated kidney transplantations.

### MATERIALS AND METHODS

### Literature search

The review was conducted in accordance with the guidelines described in the Cochrane handbook for the systematic review and meta-analysis of interventions.

### Eligibility criteria and study characteristics

The criteria for studies included the following: (1) the patients considered had undergone living related or unrelated kidney transplantations; (2) the study involved the comparison of the outcomes in patients whom underwent kidney transplantation from related *vs* unrelated kidney donations; and (3) the primary outcome was long-term (ten years) graft survival rate, while the secondary outcomes were short-term (one year) and mid-term (one to five years) graft survival rate and acute rejection rate.

Both English language studies and non-English language studies were included in the meta-analysis.

### Study identification and data abstraction

Two independent reviewers completed a systematic computerized search of online databases, including PubMed, Ovid, MEDLINE, EMBASE, the Cochrane Controlled Trials Register, HealthSTAR, CINAHL, Google, and Google Scholar to locate studies exploring the evaluation outcomes of patients who underwent kidney transplantation from living related vs unrelated kidney donations published in any language throughout March 2016. The keywords used for the search included kidney transplant, related, unrelated, and living. Thereafter, a search on MEDLINE was refined to clinical trials. We also searched the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, Clinical Trials (www.clinicaltrials.gov), Centre watch (www.centerwatch.com), Trials Central (www. trialscentral.org/ClinicalTrials.aspx), and the United Kingdom National Research Register (www.nrr.nhs.uk).

After reviewing the titles of these studies, we retrieved the abstracts that were appropriate for use in our study. We independently reviewed these abstracts and chose those studies that were potentially relevant to our work. We reviewed the bibliographies of all of the studies that were included to identify any additional studies which required inclusion. A dataextraction form was designed and agreed upon by the authors. Initially, two authors independently extracted the data, which were later reviewed jointly to reach an agreement on its accuracy. The data that were collected from all the manuscripts included the following fields: Number of patients, mean follow-up, recipient mean age, recipient sex, Immunosuppression regimen, the short-term, mid-term and long-term survival rate and the acute rejection rate, mean serum creatinine at 1 year and final follow-up, and post-transplant infectious complications. Disagreements were resolved by consensus or consultation with senior authors (Table 1). The authors of individual trials were contacted directly to provide additional information when necessary. We analysed the quality of studies with a questionnaire and only the studies that had a score greater than eight were included in our study (Table 2). In cases where the full text or data were not accessible, we tried to contact the authors in order to have them provided.



### Simforoosh N et al. Living related vs unrelated kidney transplantation

### Table 1 Study design

Literature Keyword search in PubMed, Google scholar and Scopus Search Databases Pubmed, Ovid, MEDLINE, EMBASE, the Cochrane Controlled Trials Register, HealthSTAR, CINAHI, Google, and Google Scholar Only comprehensive articles without time limit Humans In English Keywords Kidney transplantation Renal transplant Related Unrelated Eligibility Article in Full-text (no abstracts) Reported each of the interested outcomes (graft survival rate, and acute rejection rate) Outcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% different study reporting on the same parameters (prevents bias toward approaches with more experience in values between text adtabase table form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% different study reporting on the same parameters (prevents bias toward approaches with more experience (in values between text adtabase table form (each surgical approach was reported as a deparate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% different study reporting on the same parameters (prevents bias toward approaches with more experience (or vervets bias toward approaches with more experience do treater to vith countin each of outcome abstraction of interest to be included in the analysis Data were abstracted by nor reviewer and other 50% with other one. The data for 50% of the articles with dude analysis All primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study; Those necessary to determine the indeviation dinking the QASs were reported for each study, they were not used to weight the studies in the meta-analysis Primary outcomes Secondary Acute rejection rate Date defined 1 = adequately 2 = optimal 2 = ce			
InternativeKeyword search in Publick, Googe schoar and scopus1 = small but posDatabasesPubmed, Ovid, MEDLINE, EMBASE, the Cechrane Google, and Google Scholar0 = quasi-random Ure the outcomesLimitsOnly comprehensive articles without time limit Humans Renal transplant Related Urrelated Corteria0 = no mention, it adjustmentKeywordsKidney transplantation Related Urrelated Urrelated Urrelated Original reports as determined from reading the abstract or if necessary the full text could on thave > 10% difference in values between text and tables2 = withdrawals c 0 = no mention, it adjustmentOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding yr on the same parameters (prevents fouble counting) Early case experience (prevents bias toward approaches of interest to be included in adjusis 1 = withdrawals c 0 = not possible, c to the one cheat and tables 0 = not possible, c to the one cheat as form of the analysis 0 = not possible, c to the one cheat and ysis 2 = care program 2 = carely define 1 = idequity define entered by a second individual, and any discrepancies were resolved through repeated review and discussion any discrepancies resolved Variables in four types were abstracted by wore independent reviewers using the total QASS (Table 3) to assess the methodological quality of the strukes that were included in clusion and exclusion criteria, surgical approaches were head to from each study. Those necessary to determine 1 = idequated y define	Patients	Patients underwent kidney transplantation	Was the assigned tr
Sardin Databases Pubmed, Ovid, MEDLINE, EMBASE, the Cochrane Controlled Trials Register, HealthSTAR, CINAHL, Google, and Google Scholar Limits Only comprehensive articles without time limit Humans Nenal transplant Keywords Keywords Kidney transplantation Related Unr	Literature	Keyword search in PubMed, Google scholar and Scopus	2 = method did no
DatabasesProfined, Over, PlashBayBay, PlashBayBay, CLNAHE, Google, and Google ScholarWere the outcomesLimitsOnly comprehensive articles without time limit Humans In English Reinder transplant Related1 = withdrawals 1 a = withdrawals 1 a = withdrawals 2 a = withdrawals 1 a = withdrawals 2 = effective actio 2 = effective actio 2 = effective actio 1 = small or mode 0 = no mention, in adjustmentKeywordsKidney transplantation Related Unrelated0 = no mention, in adjustmentEligibilityArticle in Full-text (no abstracts) Unique publication (no duplicate articles) original report as determined from reading the abstract or of in cecsary the full text confounding tratements, no missing or unreliable data; could on thave > 10% difference in values between text and tables2 = effective actio 2 = effe	search		-
Limits Only comprehensive articles without time limit Humans 1 English 2 withdrawals 0 = no mention, in adjustment Keywords Kidney transplantation Related 1 = small or mode Renal transplant 2 = difference in adjustment 2 = difference 2 = differen	Databases	Pubmed, Ovid, MEDLINE, EMBASE, the Cochrane	-
Limits Only comprehensive articles without time limit Imits Only comprehensive articles without time limit Humans Humans Keywords Kidney transplantation Renal transplant Renal transplant Renal transplant Renal transplant Renal transplant Related Limits Unique publication (no duplicate articles) criteria Unique publication (no duplicate articles) Reported each of the interested outcomes (graft survival rate, and acute rejection rate) Original report as determined from reading the abstract or if necessary the full text Outcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables Reported on surgical approaches of interest Duplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents toal paproaches with more experienced surgeons) Data abstraction of interest to be included in the analysis Data were abstracted by two individuals into a custom of interest to be included in the analysis Data were abstracted by two individuals into a custom inclusion and exclusion criteria, surgical approach, were resolved through repeated review and discussion prior to data analysis Vare the intervention abstracted from each study; Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two indireduals into a custom inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies thar were included. Although the QASs were reported for each study, they were net used to weight the studies in the meta-analysis Frimary Secondary Acute rejection rate outc		Controlled Trials Register, HealthSTAR, CINAHL,	
LimitsOnly comprehensive articles without time limit1 = withdrawals ofHumansIn English0 = no mention, itKeywordsKidney transplantationadjustmentRenalt TansplantRelated2 = effective actioRelatedUrrelated0 = not mentionedEligibilityArticle in Full-text (no abstracts)Were the outcomescriteriaUnique publication (no duplicate articles)Original report as determined from reading the abstract0 = not mentionedOriginal report as determined from reading the abstract0 = large potentiaanalysisoutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional could not have > 10% difference in values between text and tables1 = confoundingExclusionDuplicate patient population, where some or all of the were the same patients were included in a different study reporting on the same patients experience (prevents bias toward approaches with more experience surgeons)0 = not possible, o 0 = not definedData abstractionArticles needed to report which contain each of outcome abstracted form each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes2 = clearly define protocolAll primary outcomes were text end prior to data analysis1 = clearly defined methodological quality of the studies that were included. I = inadequalty		Google, and Google Scholar	
Humas In English0 = no mention, in adjustmentKeywordsKidney transplantation Renal transplant2 = effective action 2 = good comparts 2 = good	Limits	Only comprehensive articles without time limit	
KeywordsKidney transplantation Renal transplant RelatedadjustmentKeywordsKidney transplantation Related2 = effective action a = small or mode of = not mentioned contounders may be criteria1 = small or mode of = not mentioned contounders may be criteria2 = effective action contounders may be contounders may be contounding trantments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding to analysisExclusionDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) atabase table including its of variables. S0% of articles unt out done2 = effective action a = small or mode 0 = not possible, c 0 = not mentioned Were the inclusion 0 = not mentioned Were the inclusion 0 = not mentioned Were the inclusion 0 = not defined 0 = not defined Were the inclusion 0 = not def			
KeywordsKindley transplantationWere the outcome to 2 = effective actio 2 = effective actio 1 = small or mode 0 = not mentioned 0 = not possible, o 0 = not mentioned 0 = not possible, o 0 = not possible, o 0 = not mentioned 0 = not possible, o 0 = not mentioned 0 = not possible, o 0 = not mentioned 0 = not possible, o 0 = not defined 0 = not mentioned 0 = not defined 0 = not defined 0 = not defined, n 0 = not defi		0	
Related2 = effective actioEligibilityArticle in Full-text (no abstracts)1 = small or modicriteriaUnique publication (no duplicate articles)Were the treatmentcorfounders and acute rejection rate)0 = not mentionedOriginal report as determined from reading the abstract0 = large potentiaorif necessary the full text2 = good compareapproach was reported as a separate cohort, no additional0 = large potentiacould not have > 10% difference in values between textand tablescould not have > 10% difference in values between textand tablesExclusionDuplicate patient population, where some or all of thecriteriasame patients were included in a different study reportingon the same parameters (prevents bas toward approaches0 = not possible, ofbataArticles needed to report which contain each of outcomeabstractionof interest to be included in the analysisDataArticles needed to report which contain each of outcomeabstracted by two individuals into a custom2 = care programdatabase table including list of variables. 50% of articles0 = not mentionedwere abstracted by two individuals, and any discrepancies2 = clearly definedwere esolved through repeated review and discussion1 = inadequately.outcomesAult off or each study. Those necessary to determine1 = clearly definedinclusion and exclusion criteria, surgical approach,2 = clearly definedabstracted by one dot difter studies that were included.1 = inadequately. <td>Keywords</td> <td>• •</td> <td>,</td>	Keywords	• •	,
Unrelated1 = small or modeEligibilityArticle in Full-text (no abstracts)0 = not mentionedcriteriaUnique publication (no duplicate articles)Were the treatmentReported each of the interested outcomes (graft survival rate, and acute rejection rate)2 = good compareOriginal report as determined from reading the abstract or if necessary the full text2 = good compareOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional condunding treatments, no missing or unreliable dat; could not have > 10% difference in values between text and tables0 = not possible, or but not doneExclusionDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents bas toward approaches on the same parameters (prevents double counting)1 = small or mode 0 = not possible, or but not doneDataArticles needed to report which contain each of outcome abstracted by ere reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies were abstracted by two indipendent any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis1 = clearly defined protocol is not sta 2 = clearly defined protocol is not sta 2 = clearly defined <b< td=""><td></td><td>•</td><td>2 = effective action</td></b<>		•	2 = effective action
EligibilityArticle in Full-text (no abstracts)0 = not mentionedcriteriaUnique publication (no duplicate articles)Were the treatmentReported each of the interested outcomes (graft survival rate, and acute rejection rate)2 = good compartOriginal report as determined from reading the abstract or if necessary the full text2 = good compartOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text ame patients were included in a different study reporting on the same parameters (prevents double counting)2 = effective actio 2 = effective actio 1 = small or modd 0 = not possible, o but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom prior to data analysis3 = not mentioneed Were the treatment 2 = effective actio 1 = small or modd 0 = not possible, o but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom prior to data analysis2 = care program 2 = clearly defined protocol is not sta 0 = not defined 2 = clearly defined protocol is not sta 0 = intervention a 2 = clearly defined protocol is not sta 0 = int defined were the induction 0 = not defined 0 = not defined 0 = not definedData abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, an			1 = small or mode
criteriaUnique publication (no duplicate articles) Reported each of the interested outcomes (graft survival rate, and acute rejection rate)Were the treatment confoundings may be chronic injury)Original report as determined from reading the abstract or if necessary the full text2 = good compare analysisOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding s 0 = large potentiaExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents bias toward approaches with more experience (prevents bias toward approaches of interest to be included in the analysis2 = effective actio 1 = small or mode 0 = not possible, o but not doneData abstractionO interest to be included in the analysis Data were abstracted by two individuals into a custom database table including list of variables. 50% of atticles were resolved through repeated review and discussion prior to data analysis2 = care program 1 = clearly definee protocolAll primary outcomes vere no tused to weight the studies in the meta-analysis2 = clearly definee protocol is not sta 0 = inot defined. 1 = clearly definee protocol is not sta 0 = inot defined.Primary outcomesGraft survival rate outcomes2 = clearly definee protocol is not sta 0 = not defined.Primary outcomesCraft survival rate 0 = not defined, no Were diagnostic te outcomes2 = cariy definee protocol is not st	T1: -: 1-: 1: (		0 = not mentioned
Reported each of the interested outcomes (graft survival rate, and acute rejection rate)contounders may be contronic injury)Original report as determined from reading the abstract or if necessary the full text2 = good compar- analysisOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = large potentia Were the participar 2 = effective actio 1 = small or mode 0 = not possible, c but not doneExclusion criteriaReported on surgical approaches of interest same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents double counting) Data abstraction1 = small or mode 0 = not possible, c but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom of interest to be included in the analysis mother one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies mothodological quality of the studies in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes2 = clearly define to = intervention a 2 = clearly defined to = intervention a 2 = clearly defined to = intervention a 2 = clearly defined to = not defined, m Were the surveilland 2 = active surveillPrimary controls for Publication biasCanter spectoin rate 0 = not de		· · · · · · · · · · · · · · · · · · ·	Were the treatment
rate, and acute rejection rate)chronic injury)0 "rate, and acute rejection rate)0 "rote control0 "riginal report as determined from reading the abstract or if necessary the full text2 = good compare analysis0 Utcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding t e affective actio 0 = not possible, o but not doneExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents bias toward approaches with more experienced surgeons)Were the treatment 2 = affective actio 0 = not possible, o but not doneData abstractionArticles needed to report which contain each of outcome abstracted by were abstracted by two individuals into a custom database table including list of variables. 50% of articles were abstracted by one reviewer and discussion prior to data analysis2 = clearly definee 1 = inadequately. 0 = not defined Were the interventi 2 = clearly definee protocol is not sta 0 = intervention a 2 = clearly definee 1 = clear but trivi 0 = not defined Were the autore 2 = clearly definee 2 = optimal 1 = clearly definee 2 = optimal 1 = clearly definee 2 = optimal 2 = optimal 1 = adequated 0 = not defined Were tideined, n Were diagnostic tes outcomesPrimary controls for Performed a funnel plot analysis2 = optimal 1 = adequate 0 = not defined, n Was the surveillandPrimary biasPerformed a funnel pl	criteria		confounders may b
Original report as determined from reading the abstract or if necessary the full text2 = good compare analysisOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding tre e = effective actio 1 = small or mode 0 = not possible, c but not doneExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents buist toward approaches with more experienced surgeons)2 = effective actio 1 = small or mode 0 = not possible, c but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom database table including list of variables. 50% of articles were resolved through repeated review and discussion prior to data analysis2 = clearly defined 1 = clearly defined 2 = clearly defin			chronic injury)
or if necessary the full textanalysisOutcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding te e Heratticipat confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding te e Heratticipat confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = confounding te e Heratticipat 2 = effective actio 1 = small or mode 0 = not possible, c but not doneExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents bias toward approaches of interest to be included in the analysis Data were abstracted by two individuals into a custom database table including list of variables. 50% of articles were resolved through repeated review and discussion prior to data analysis2 = caer program Care program 2 = caerly defined 1 = inadequately 0 = not defined 0 = intervention a 2 = clearly defined reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis2 = clearly defined 1 = inadequately 0 = not defined 1 = inadequately 0 = not defined 1 = inadequately 0 = not definedPrimary outcomesQerformed a funnel plot analysis2 = optimal 1 = active surveillPrimary outcomesPerformed a funnel plot analysis2 = optimal 1 = active surveillPrimary biasPerformed a funnel plot analysis<			2 = good compara
Outcome reported in a usable form (each surgical approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables1 = contounding : Control have > 10% difference in values between text and tablesExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)Uut not doneData abstractionArticles needed to report which contain each of outcome database table including list of variables. 50% of articles were abstracted by two individuals into a custom database table including list of variables. 50% of articles were resolved through repeated review and discussion prior to data analysis2 = clearly definee the inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All primary outcomes were then double-checked and and listudies were reviewed by two independent reviewers using the total QASS (Table 3) to assess the methodological quality of the studies in the meta-analysisWere the autement 2 = clearly definee protocol 1 = clearly defined protocol is not stat 0 = not defined Were diagnostic tex 2 = clearly defined protocol is not stat 0 = not defined Were diagnostic texPrimary outcomesCarft survival rate outcomes2 = optimal 1 = adequately 0 = not defined were not used to weight the studies in the meta-analysis 0 = not defined were not used to weight the studies in the meta-analysis 2 = clearly definee 2 = clearly definee 2 = clearly definee 2 =		· · ·	analysis
approach was reported as a separate cohort, no additional confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables Exclusion criteria same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons) Data abstraction Data were abstracted by two individuals into a custom database table including list of variables. 50% of articles were abstracted by one reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies were resolved through repeated review and discussion prior to data analysis All primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study. Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis Primary outcomes Executions Controls for Controls for Publication Controls for Controls for Purbication		5	1 = confounding s
confounding treatments, no missing or unreliable data; could not have > 10% difference in values between text and tables2 = effective actio 1 = small or mode 0 = not possible, o but not doneExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)2 = effective actio 1 = small or mode 0 = not possible, o 0 = not mentioned Were care program 2 = care program 2 = care program 0 = not mentioned Were the inclusion 0 = not defined 2 = clearly defined any discrepancies resolved through repeated review and discussion prior to data analysis2 = clearly defined 0 = not defined Were the inclusion 2 = clearly defined protocol 1 = clearly defined protocol 1 = clearly defined protocol 1 = clearly defined were the outcomesPrimary outcomesGraft survival rate outcomes2 = clearly defined protocol is not stato 0 = not defined were disquately. 0 = not defined were the outcomesPrimary outcomesPerformed a funnel plot analysis2 = optimal 1 = active surveilland 2 = active surveilland 2 = active surveilland 2 = active surveillandPublicationPerformed a funnel plot analysis2 = a		-	0 = large potentia
could not have > 10% difference in values between text and tables       1 = small or mode 0 = not possible, o but not done         Exclusion criteria       Duplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting)       2 = effective actio 1 = small or mode 0 = not possible, o but not done         Data       Articles needed to report which contain each of outcome abstraction       1 = small or mode 0 = not possible, o but not done         Data       Articles needed to report which contain each of outcome database table including list of variables. 50% of atricles       0 = not possible, o but not done         Were care programs       2 = care programs       2 = care programs         Data       Articles needed to report which contain each of outcome were abstracted by two individuals into a custom other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies were resolved through repeated review and discussion prior to data analysis       2 = clearly defined to = not defined         All primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis       2 = clearly defined were the adequately to a = not defined         Primary       Graft survival rate outcomes       2 =			Were the participar
and tables0 = not possible, of but not doneExclusion criteriaDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)0 = not possible, of but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis0 = not possible, of but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis0 = not possible, of but not doneData abstractionArticles needed to report which contain each of outcome were abstracted by two individuals into a custom other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies reviewer susing the toal QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis0 = not defined u = clearly defined i = clea		0	
Reported on surgical approaches of interestbut not doneExclusionDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)Uere the treatment 2 = effective actio 0 = not possible, o but not doneDataArticles needed to report which contain each of outcome abstractionI = small or mode 0 = not possible, o but not doneDataArticles needed to report which contain each of outcome abstracted by two individuals into a custom of interest to be included in the analysisZ = care program 2 = care program 2 = care program 2 = care program 2 = care program 0 = not mentioned 0 = not mentioned 0 = not defined 2 = clearly defined 1 = inadequately o 0 = not defined 2 = clearly defined any discrepancies resolved Variables in four types were abstracted from each study. Those necessary to determine inclusion and exclusion criteria, surgical approach, All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysisWere the outcome 0 = not defined 1 = inadequately outcomesPrimaryGraft survival rate outcomes2 = optimal 1 = adequate 0 = not defined, n 0 = not defined, nPublicationPerformed a funnel plot analysis2 = optimal 1 = active surveill 1 = active surveill		and tables	
ExclusionDuplicate patient population, where some or all of the same patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)Util to the Were the treatment 2 = effective actio 0 = not possible, o but not doneData abstractionArticles needed to report which contain each of outcome abstracted by ene reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies resolved through repeated review and discussion prior to data analysis2 = clearly defined 0 = not defined 0 = not defined 0 = not definedAll primary outcomes were then double-checked and any discrepancies resolved through repeated review and discussion any discrepancies resolved Variables in four types were inclusion and exclusion criteria, surgical approach, All studies were reviewed by two independent reviewers using the total QASs (Table 3) to asses the methodological quality of the studies in the meta-analysisWere the interventi 2 = clearly defined protocol is not stad 0 = not defined 0 = not defined, n 0 = not defined, n		Reported on surgical approaches of interest	
criteriasame patients were included in a different study reporting on the same parameters (prevents double counting) Early case experience (prevents bias toward approaches with more experienced surgeons)Were the includent 1 = small or mode 0 = not possible, or but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis0 = not possible, or but not doneData abstractionArticles needed to report which contain each of outcome database table including list of variables. 50% of articles were abstracted by one reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies were resolved through repeated review and discussion prior to data analysis0 = not mentioned Were the inclusion 0 = not definedAll primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis0 = intervention a 2 = clearly defined 1 = inadequately 0 = not definedPrimary outcomesGraft survival rate 0 = not defined2 = optimal 1 = adequate 0 = not definedPublication biasPerformed a funnel plot analysis0 = not defined 0 = not definedPublicationPerformed a funnel plot analysis0 = not defined 0 = not definedPublicationPerformed a funnel plot analysis2	Exclusion		
on the same parameters (prevents double counting)1 = small or modeEarly case experience (prevents bias toward approaches with more experienced surgeons)0 = not possible, or but not doneDataArticles needed to report which contain each of outcome of interest to be included in the analysis2 = care program 2 = clearly defined 2 =	criteria		
Early case experience (prevents bias toward approaches with more experienced surgeons)0 = not possible, o but not doneData abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom database table including list of variables. 50% of articles were abstracted by one reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies were resolved through repeated review and discussion prior to data analysis0 = not mentioned Were the inclusion 0 = not defined 1 = inadequately 0 = not definedAll primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies in the meta-analysis2 = clearly defined protocol is not stat 0 = not definedPrimary outcomesGraft survival rate outcomes0 = not defined were diagnostic tes outcome)Primary outcomesCraft survival rate 0 = not defined, no was the surveillandPublication publicationPerformed a funnel plot analysisWas the surveilland 2 = active surveill1 = active surveill1 = active surveill		on the same parameters (prevents double counting)	
With more experienced surgeons)but not doneDataArticles needed to report which contain each of outcome of interest to be included in the analysisWere care program 2 = clearly defined 2 = clearly defined <td></td> <td>Early case experience (prevents bias toward approaches</td> <td></td>		Early case experience (prevents bias toward approaches	
Data abstractionArticles needed to report which contain each of outcome of interest to be included in the analysis Data were abstracted by two individuals into a custom 		with more experienced surgeons)	
abstractionof interest to be included in the analysis2 = care programeData were abstracted by two individuals into a custom database table including list of variables. 50% of articles1 = clear but trivia 0 = not mentioned Were the inclusion 0 = not defined 1 = inadequately 0 = not defined 1 = inadequately 0 = not defined 0 = not defined 2 = clearly definee 1 = inadequately 0 = not defined 0 = intervention a 0 = not defined 0 = n	Data	Articles needed to report which contain each of outcome	
Data were abstracted by two individuals into a custom1 = clear but triviadatabase table including list of variables. 50% of articles0 = not mentionedwere abstracted by one reviewer and other 50% withWere the inclusionother one. The data for 50% of the articles was double-2 = clearly definedentered by a second individual, and any discrepancies1 = inadequatelywere resolved through repeated review and discussion0 = not definedprior to data analysisWere the interventiAll primary outcomes were then double-checked and2 = clearly definedabstracted from each study: Those necessary to determine1 = clearly definedinclusion and exclusion criteria, surgical approach,protocol is not statbaseline patient characteristics, and clinical outcomes0 = intervention aAll studies were reviewed by two independentWere the outcome to enteredreviewers using the total QASs (Table 3) to assess the2 = clearly definedwere not used to weight the studies in the meta-analysisWere diagnostic tesPrimaryGraft survival rateoutcome)outcomes2 = optimalsecondaryAcute rejection rate1 = adequateoutcomes0 = not definedpublication2 = active surveillbias1 = active surveill	abstraction	of interest to be included in the analysis	
were abstracted by one reviewer and other 50% with other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies prior to data analysis0 = not defined 1 = inadequately 0 = not defined 2 = clearly defined 0 = not defined 0 = not defined 2 = clearly defined 0 = not defined 0 = not defined 2 = clearly defined 0 = not defined 0 = interventin 1 = clearly defined 0 = intervention a 0 = not defined 0 = not defined, n 0 = not defined,		-	1 = clear but trivia
other one. The data for 50% of the articles was double- entered by a second individual, and any discrepancies2 = clearly definedentered by a second individual, and any discrepancies1 = inadequatelywere resolved through repeated review and discussion prior to data analysis0 = not definedAll primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes1 = clearly definedAll studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis2 = clearly definedPrimaryGraft survival rate outcomes0 = not definedoutcomes0 = not defined1 = inadequatelyPublication2 = optimal2 = clearly definedSecondaryAcute rejection rate1 = adequateoutcomes0 = not defined2 = clearly definedPublication2 = active surveillandPublication2 = clearly definedbias1 = active surveilland		-	0 = not mentioned
entered by a second individual, and any discrepancies1 = inadequatelywere resolved through repeated review and discussion0 = not definedprior to data analysisWere the interventiAll primary outcomes were then double-checked and2 = clearly definedany discrepancies resolved Variables in four types wereprotocolabstracted from each study: Those necessary to determine1 = clearly definedinclusion and exclusion criteria, surgical approach,protocol is not statbaseline patient characteristics, and clinical outcomes0 = intervention aAll studies were reviewed by two independentWere the outcome reviewers using the total QASs (Table 3) to assess the2 = clearly definedmethodological quality of the studies in the meta-analysisWere diagnostic tesPrimaryGraft survival rateoutcome)outcomes0 = not definedsecondaryAcute rejection rate1 = adequateoutcomes0 = not definedpublication2 = optimalfeature1 = active surveillbias1 = active surveill			Were the inclusion
were resolved through repeated review and discussion prior to data analysis0 = not defined 0 = not defined Were the intervention 2 = clearly defined protocolAll primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes1 = clearly defined protocol is not state 0 = intervention a 0 = intervention a 0 = not definedAll studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysisWere diagnostic test outcomesPrimaryGraft survival rateoutcome)2 = optimal 1 = adequateSecondaryAcute rejection rate0 = not defined, nControls forPerformed a funnel plot analysisWas the surveilland 2 = active surveillPublication2 = active surveillbias1 = active surveill			2 = clearly defined
Note the definedprior to data analysisWere the interventionAll primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes1 = clearly defined protocol is not stat 0 = intervention and Were the outcomesAll studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis0 = not defined user et alagnostic tesPrimaryGraft survival rate outcomes0 = not defined 1 = adequateoutcomes0 = not defined a funnel plot analysis0 = not defined 1 = active surveillPublication2 = optimal 1 = active surveillbias1 = active surveill			1 = inadequately
All primary outcomes were then double-checked and any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysisWere diagnostic test outcomesPrimaryGraft survival rate outcomes0 = not defined u = adequateOutcomes0 = not defined u = adequatePublicationPerformed a funnel plot analysisWas the surveilland u = active surveillPublication2 = active surveill		0 1	0 = not defined
any discrepancies resolved Variables in four types were abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, protocol is not stat baseline patient characteristics, and clinical outcomes1 = clearly defined protocol is not stat 0 = intervention a 4.11 studies were reviewed by two independentWere the outcome outcomes 0 = intervention aAll studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis0 = not defined uere diagnostic tes outcomesPrimaryGraft survival rate outcomes0 = not defined 1 = adequateOutcomes0 = not defined a funnel plot analysis1 = adequate 0 = not defined, nPublicationPerformed a funnel plot analysisWas the surveilland 2 = active surveillDiag1 = active surveill1 = active surveilland		1	
abstracted from each study: Those necessary to determine inclusion and exclusion criteria, surgical approach, baseline patient characteristics, and clinical outcomes1 = clearly defined protocol is not sta 0 = intervention a Were the outcome previewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included.1 = inadequately o = not defined were not used to weight the studies in the meta-analysisPrimaryGraft survival rate outcomes0 = not defined outcomesSecondaryAcute rejection rate outcomes2 = optimal 1 = adequate out defined a funnel plot analysisPublicationPerformed a funnel plot analysisWas the surveilland 2 = active surveill 1 = active surveill			
inclusion and exclusion criteria, surgical approach, protocol is not stat baseline patient characteristics, and clinical outcomes All studies were reviewed by two independent reviewers using the total QASs (Table 3) to assess the reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis Primary Graft survival rate outcomes Secondary Acute rejection rate outcomes Controls for Performed a funnel plot analysis Publication Publication Defined a funnel plot analysis Publication Defined a funnel plot analysis Publication Defined a funnel plot analysis Publication Defined a funnel plot analysis Defined a funne			•
baseline patient characteristics, and clinical outcomes0 = intervention atAll studies were reviewed by two independentWere the outcome atreviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included.2 = clearly definedAlthough the QASs were reported for each study, they were not used to weight the studies in the meta-analysis0 = not definedPrimaryGraft survival rateoutcome)outcomes2 = optimalSecondaryAcute rejection rate1 = adequateoutcomes0 = not definedPublication2 = active surveillbias1 = active surveill			-
All studies were reviewed by two independent       Were the outcome and the period of the studies of the studies of the studies studies that were included.       2 = clearly defined         reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included.       1 = inadequately of the studies that were included.         Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis       0 = not defined         Primary       Graft survival rate       outcome)         outcomes       2 = optimal         Secondary       Acute rejection rate       1 = adequate         outcomes       0 = not defined       0 = not defined         Publication       Performed a funnel plot analysis       Was the surveilland         Publication       2 = active surveilland         bias       1 = active surveilland			1
reviewers using the total QASs (Table 3) to assess the methodological quality of the studies that were included. Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis Primary Graft survival rate outcomes Secondary Acute rejection rate outcomes Controls for Performed a funnel plot analysis Publication Publication Defined Terformed a funnel plot analysis Publication Terformed a funnel plot analysis Publication Defined Terformed Te		-	
methodological quality of the studies that were included.1 = inadequatelyAlthough the QASs were reported for each study, they were not used to weight the studies in the meta-analysis0 = not definedPrimaryGraft survival rateoutcome)outcomes2 = optimalSecondaryAcute rejection rate1 = adequateoutcomes0 = not defined, mControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill			
Although the QASs were reported for each study, they were not used to weight the studies in the meta-analysis0 = not defined Were diagnostic tesPrimaryGraft survival rateoutcome)outcomes2 = optimalSecondaryAcute rejection rate1 = adequateoutcomes0 = not defined, mControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill			2
were not used to weight the studies in the meta-analysisWere diagnostic testPrimaryGraft survival rateoutcome)outcomes2 = optimalSecondaryAcute rejection rate1 = adequateoutcomes0 = not defined, mControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillandbias1 = active surveilland			
PrimaryGraft survival rateoutcome)outcomes2 = optimalSecondaryAcute rejection rate1 = adequateoutcomes0 = not defined, nControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill		were not used to weight the studies in the meta-analysis	
SecondaryAcute rejection rate1 = adequateoutcomes0 = not defined, nControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill	Primary	Graft survival rate	
outcomes0 = not defined, nControls forPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill	outcomes		2 = optimal
Controls for PublicationPerformed a funnel plot analysisWas the surveillandPublication2 = active surveillbias1 = active surveill	Secondary	Acute rejection rate	1 = adequate
Publication     2 = active surveill       bias     1 = active surveill	outcomes		0 = not defined, n
bias 1 = active surveill		Performed a funnel plot analysis	Was the surveillance
			2 = active surveill
0 = surveillance n	bias		1 = active surveill
			0 = surveillance n

QASs: Quality assessments.

### Statistical analysis

The Review Manager Database (RevManversion 5.0, The Cochrane Collaboration 2008) was used to analyse the selected studies. Continuous data for each arm of a particular study were expressed as mean and standard deviation. Dichotomous data were expressed as pro-

### Table 2 Quality assessment items and possible scores

treatment adequately concealed prior to allocation? not allow disclosure of assignment

sible chance of disclosure of assignment or unclear nized or open list/tables

s of participants who withdrew described and alysis (intention-to-treat)?

well described and accounted for in analysis

described and analysis not possible

inadequate mention, or obvious differences and no

assessors blinded to treatment status?

on taken to blind assessors

lerate chance of unblinding of assessors

ed or not possible

nt and control groups comparable at entry? (likely be age, partial or total rupture, activity level, acute or

ability of groups, or confounding adjusted for in

small; mentioned but not adjusted for

al for confounding, or not discussed

ants blind to assignment status after allocation?

on taken to blind participants

lerate chance of unblinding of participants or not mentioned (unless double-blind), or possible

nt providers blind to assignment status?

on taken to blind treatment providers

lerate chance of unblinding of treatment providers or not mentioned (unless double-blind), or possible

nes, other than the trial options, identical?

nes clearly identical

ial differences

d or clear and important differences in care programes and exclusion criteria clearly defined?

d

defined

tions clearly defined?

ed interventions are applied with a standardized

ed interventions are applied but the application andardized

and/or application protocol are poorly or not defined measures used clearly defined? (by outcome)

- ed
- defined

ests used in outcome assessment clinically useful? (by

- not adequate
- ce active, and of clinically appropriate duration?
- llance and appropriate duration
- llance, but inadequate duration
- not active or not defined

portions or risks, with the treatment effect reported as a relative risk with 95%CI.

The data were analysed for the outcomes that were of interest to us. The risk ratio (RR) was defined as the number of patients with a successful graft survival rate. The RR referred to the multiplication of the rate of graft

surveillance that occurred with the use of related and unrelated kidney transplantations. The heterogeneity between the studies was assessed using the  $\chi^2$  test and the  $I^2$  statistic. The latter is a measure of the percentage of variation in data that results from heterogeneity as opposed to chance. A *P* value of < 0.1 and an  $I^2$ value > 50% were considered suggestive of statistical heterogeneity, prompting a random effects modelling estimate. Conversely, a non-significant chi-squared test result (a *P* value  $\geq$  0.1 and an  $I^2$  value  $\leq$  50%) only suggested that there was no evidence of heterogeneity; it did not necessarily imply that homogeneity existed because there may have been insufficient power to detect heterogeneity. The Mantel-Haenszel (M-H) method was used to combine the studies. If their significant heterogeneity were indicated (P < 0.1 and  $I^2 > 50\%$ ), a random-effect model was used; if not, a fixed-effect model was used. In addition, funnel plots were constructed for the outcomes to assess publication bias, i.e., the tendency not to publish studies with negative results; the more asymmetric the funnel plot is, the more potential bias there is. The statistical significance was set at P < 0.05.

### RESULTS

### Study selection

Using our search terms, 376 references were identified. The first search of studies exploring the evaluation of the outcomes of patients yielded the following results: PubMed (n = 11590), Ovid (n = 24), EMBASE (n = 3300), the Cochrane Controlled Trials Register (n = 9719), and Google Scholar (n = 1430). Out of these, we included 12 studies after applying our eligibility criteria to their titles and/or abstracts, excluding duplicates (Figure 1).

The eligible trials included 12 relevant comparisons (Table 3) involving 9954 participants. We could not assess the differences in the outcomes between postoperative infections, post-operative hypertension, diabetes, and post-operative creatinine due to the lack of data.

### Study presentation

Cortesini *et al*<sup>[9]</sup> evaluated 527 kidney allografts from living donors. Of these, 302 living donors were first-degree relatives of the recipient and shared one haplotype (living related donor) and 172 were unrelated. They showed actuarial graft survival rates in the living related and living unrelated groups, which were 91% and 87% in 1 year, 77% and 79% in 5 years, and 66% and 69% in 9 years. In conclusion, they reported that kidney transplantation between unrelated donors and recipients might be a valid alternative in view of the cadaver organ shortage, its success as a procedure and its potential to provide the "gift of life" to both the patient and the family.

Voiculescu *et al*<sup>[10]</sup> evaluated 62 out of 112 potential

living donors for types of rejections, complications, and kidney functions. Of them, 38 cases were living related and 24 cases were living unrelated. They showed that acute rejection rate was similar in both groups (52.2% vs 54.2%); however, there were more complications of infection in the living related group (66.7% vs 36.4%) and a trend showing more surgical complications in living related transplantations (28.9% vs 8.3%). They concluded that the results for the living unrelated group are equivalent to the living related transplantation group. They determined that careful selection of donors and recipients is a prerequisite for success.

Kizilisik *et a*<sup>[11]</sup> evaluated 109 living donor kidney transplants. Seventy-eight percent of living donors were from living related donors and 22% were from living unrelated donors. The resultant one- and three-year patient survival rates were 97.6% and 93.2%, with 1and 3-year graft survival rates of 93.2% and 88.3%, respectively. Among the patients of Kizilisik *et a*<sup>[11]</sup>, there were 6 delayed graft functions (5.5%), 16 acute cellular rejections (10%), and 10 chronic rejections (9%). They suggested that living donors represent a valuable source because of the limited number of cadaveric kidneys available for transplant and stated that the use of living-unrelated donors has produced an additional supply of organs.

Park et al<sup>[12]</sup> evaluated 77 living-donor renal transplants (41 were living unrelated and 36 were living related transplants). They reported that 11 recipients lost their grafts (6 from living unrelated and 5 from living related); most of these losses were due to chronic rejection (n = 7). Overall 3-, 5- and 10-year graft survival rates in live donors were 92.8%, 86.6% and 76.9%, respectively; for the living unrelated, the graft survival at 3-, 5- and 10-years was 91.9%, 88.5% and 74.7% vs 94%, 84% and 78.8% for the living related transplants. They concluded that acute rejection episodes markedly decreased long-term graft survival in live donor renal transplants, the use of living related transplants provides graft survival comparable with living related transplants, and proper management of acute rejection is essential for long-term graft survival.

Wolters *et al*<sup>[13]</sup> evaluated 95 living donor transplantations (69% related, 31% unrelated). They showed that at a mean follow-up of 35 mo, 94.7% of grafts were functioning. Three grafts were lost due to acute (in related transplants) or chronic (in unrelated transplants) rejection or due to multi-organ failures. They concluded that although HLA mismatching was significantly different between related and unrelated donors, no difference in the outcome was observed.

Simforoosh *et al*<sup>(14)</sup>, between 1984 and 2004, evaluated 2155 kidney transplantations; out of this, 374 were from living related donors and 1760 were from unrelated donors. The resultant 1-, 3-, 5-, 10- and 15-year graft survival rates among the related group were 91.6%, 81.7%, 76.4%, 64.4% and 48.4%; and for unrelated group, these rates were 91.5%, 86.7%, 81.4%, 68.2%

Ref.	Number	Mean follow up (mo)	Recipient mean age (yr)	Recipient sex M/F	Immunosuppression regimen	One year graft survival rate	five years graft survival rate	10 yr graft survival rate	Acute rejection rate	Mean serum Cr at 1 yr	Mean serum Cr at final follow up	Post- transplant infectious complications
Cortesini <i>et al</i> <sup>[9]</sup> ,	302 vs	42	$32.8 \pm 7.3$	215/87	Cyclosporine	275 (91)	232 (77)	199 (66)	N/D	1.9 ±	$2.0 \pm 0.8$	N/D
2002	172		vs 44 ± 9.9	vs 133/39		vs 150 (87)	vs 136 (79)	vs 118 (69)		0.8 vs 2.0 ± 0.8	vs 1.9 ± 0.8	
Simforoosh <i>et al</i> <sup>[5]</sup> , 2016	411 <i>vs</i> 3305	N/D	27.6 ± 10.1 vs 35.6 ± 15.6	270/138 vs 2164/1136	Cyclosporine	89% <i>vs</i> 90%	288 (70.2) vs 2697 (81.6)	225 (54.9) vs 2350 (71.1)	N/D	N/D	N/D	N/D
Voiculescu <i>et al</i> <sup>[10]</sup> , 2003	38 vs 24	19.6 ± 15.4	37.7 ± 12.1 vs 53.6 ± 7.8	26/12 vs 14/10	Steroids, cyclosporine, mycophenolate mofetil		N/D	N/D	20 (52.5) vs 13 (54.2)	N/D	1.76 ± 0.6 vs 1.62 ± 0.5	25 (66.7) vs 9 (36.4)
Ahmad <i>et al</i> <sup>[15]</sup> , 2008	261 vs 61	45	$28 \pm 16 vs$ $48 \pm 12$	N/D	Cyclosporine	247 (94.8) <i>vs</i> 60 (98.4)	N/D	N/D	107 (41) vs 21 (35)	N/D	N/D	N/D
Kizilisik <i>et al</i> <sup>[11]</sup> , 2004	85 vs 24	36	N/D	N/D	Cyclosporine, azathioprine, steroid, tacrolimus, mycofenolatemofetil	81 (95) <i>vs</i> 23 (95.8)	75(88.3) vs 21 (87.5)	N/D	11(13) <i>vs</i> 5 (20)	N/D	N/D	7 (8.3) vs 8 (3.5)
Park <i>et al</i> <sup>[12]</sup> , 2004	36 vs 41	N/D	33.6 vs 38.3	21/15 vs 28/13	Cyclosporine, steroid and mycophenolatemofetil	N/D	30 (84) <i>vs</i> 36 (88.5)	28 (78.8) vs 41 (74.7)	11 (30) vs 13 (31)	N/D	N/D	N/D
Wolters <i>et al</i> <sup>[13]</sup> , 2005	66 vs 29	35	31 ± 12.5 vs 51 ± 8.5	41/25 vs 23/6	Cyclosporine/MMF/ prednisone <i>vs</i> MMF/prednisone	N/D	62 (94.7) vs 23 (94.7)	N/D	6 (9) vs 5 (17.2)	N/D	N/D	N/D
Simforoosh <i>et al</i> <sup>[14]</sup> , 2006	374 <i>vs</i> 1760	45.68 ± 46.80	28.97 ± 9.58 vs 33.46 ± 14.61	N/D	Cyclosporine, azathioprine, and prednisone	342 (91.6) <i>vs</i> 1610 (91.5)	(81.4) 286 (76.4) <i>vs</i> 1432 (81.4)	241 (64.4) vs 1200 (68.2)	N/D	N/D	N/D	N/D
Ishikawa <i>et al</i> <sup>[16]</sup> , 2012	66 vs 44	12	$36.1 \pm 12.4$ vs $55.0 \pm 8.8$	29/15 vs 38/28	Plasmaphresis, tacro, celecpt, Basiliximab, rituximab, methyl prednisolone, cyclosporine, deoxypergualin	65 (98.5) <i>vs</i> 43 (97.7)	N/D	N/D	16 (24.2) vs 14 (31.8)	N/D	N/D	N/D
Santori <i>et al</i> <sup>[17]</sup> , 2012	111 <i>vs</i> 24	$128.17 \pm 86.64$ vs $103.53 \pm 86.85$	26.94 ± 13.51 vs 50.04 ± 8.86	78/33 vs 18/6	Cyclosporine, tacro, steroids, celecept	N/D	N/D	71 (63.8) <i>vs</i> 21 (87.8)	N/D	N/D	N/D	N/D
Matter <i>et al</i> <sup>[18]</sup> , 2016	2075 vs 410	7.72 ± 6.15	28.8 ± 9.8 vs 34.8 ± 11.1	1554/521 <i>vs</i> 297/113	Steroid- Azathioprine or MMF	2012 (97) vs 389 (95)	1784 (86) vs 340 (83)	1660 (67) vs 270 (66)	71 (3.4) vs 26 (6.3)	$1.38 \pm 0.69$ vs $1.35 \pm 0.61$	1.71 ± 1.04 vs 1.59 ± 0.89	N/D
Ali et al <sup>[19]</sup>	92 <i>vs</i> 143	5	N/D	N/D	Methyl prednisolone, Cyclosporine or tacrolimus MMF	90 (97) vs 141 (98.6)	80 (86) vs 125 (87.4)	N/D	N/D	N/D	N/D	N/D

Data is presented as *n* (%) and Mean ± SD. N/D: Not determined; MMF: Mycophenolatemofetil.

and 53.2%, respectively. Patient survivals for 1-, 3-, 5-, 10- and 15-years in the living related group were 94.6%, 91.9%, 83%, 79.5% and 73.9%; and in the unrelated group, these were 93.6%, 91.7%, 89.3%, 84% and 76.4%, respectively. They concluded that the results of living unrelated kidney transplantation upon long-term follow-up in a large number of cases was as

effective as living related kidney transplantation.

Ahmad *et al*<sup>151</sup> retrospectively analysed the outcome of 322 living-donor renal transplants (related donors: 261; unrelated donors = 61). They reported that 33 grafts failed: 30 in the living related (11%) and 3 in the unrelated donor group (5%). Acute rejections occurred in 41% of recipients in the living related group




Figure 1 Study selection.

and 35% of recipients in the unrelated group. Oneand 3-year patient survival for the living related and unrelated group was 98.7% and 96.3% and 97.7% and 95%, respectively. One- and 3-year graft survival was equivalent at 94.8% and 92.3% for the living related, and at 98.4% and 93.7% for the living unrelated group, respectively. They concluded that the outcome of living related donors and living unrelated donors is comparable in terms of patient and graft survival, acute rejection rate, and the estimated GFR despite the differences in demographics, HLA matching, and retransplants of recipients.

Ishikawa *et al*<sup>[16]</sup> evaluated 112 cases of living kidney transplantations including 46 (41%) unrelated donors and 66 cases of received kidneys from living related donors. They showed that the incidences of an acute rejection episode were 31.8% and 24.2% in the

living unrelated and the related groups, respectively. They demonstrated that living transplantation from an unrelated group was equivalent to related ones.

Santori *et al*<sup>[17]</sup> evaluated 135 procedures using living donors (living related: 111; living unrelated: 24). They reported no significant difference in patient survival after stratifying for donor type (living related: 93.9%; unrelated donors: 95.8%) or in graft survival after stratifying for donor type (related: 63.8%; unrelated: 87.8%). After entering donor type as an independent variable in a univariate Cox regression, they showed no significance for either recipient or graft survival. They suggested that living unrelated donor utilization should be encouraged in kidney transplantation programmes.

Simforoosh *et al*<sup>(5)</sup> evaluated 3,716 kidney transplantations (411 related donors and 3305 unrelated donors). They showed that donor age was the only statistically significant predictor of graft survival rate (hazard ratio = 1.021; 95%CI: 1.012-1.031). Patient survival and graft survival was similar in transplantations from living unrelated and related donors. They concluded that transplants from LURDs might be proposed as an acceptable management for patients with end stage renal disease.

Matter *et al*<sup>[18]</sup> from March 1976 to December 2013, divided the patients into two groups: (1) 2075 kidney transplant recipients (1554 or 74.9% male and 521 or 25.1% female) for whom the donors were living related; (2) 410 kidney transplant recipients (297 or 72.4% male and 113 or 27.6% female) for whom the donors were living unrelated. They showed the percentages of patients with acute vascular rejection were significantly higher in the unrelated group, while percentages of patients with no rejection were significantly higher in the related group, but there were no significant differences regarding patient and graft survivals between both groups.

Ali *et al*<sup>[19]</sup> evaluated 250 kidney transplantations (92 related donors, 143 unrelated donors and 15 spouse). They showed the one-year graft survival for related and unrelated donor transplants was 98.9% and 91.8%, respectively. Graft survival was lower (82.9%) in recipients with acute rejection episodes. The patient survival at one-year was 94%. The three year graft and patient survival was 91% and 90%, respectively, and five-year survival for grafts and patients was 87.1% and 88%, respectively.

### Meta-analysis

**Long term (ten year) graft survival rate:** We conducted random effect meta-analyses (Figure 2) because the results from the studies which reported ten years graft survival rate after living related and unrelated renal transplantation showed significant heterogeneity (P = 0.001). No significant difference in graft survival rate was detected after ten years in patients who underwent living related kidney transplantations in comparison to

### Simforoosh N et al. Living related vs unrelated kidney transplantation




Figure 2 Significant heterogeneity in long term follow up between living related and unrelated kidney transplantation in funnel plot. RR: Risk ratio.

those who underwent unrelated kidney transplantations (P = 0.44) (Figure 3).

**Mid-term (one to five year) graft survival rate:** We conducted random effect meta-analyses because the results from studies reporting 1-5 years graft survival rate after living related and unrelated renal transplantation showed significant heterogeneity (P = 0.002). There were no significant differences between graft survival rate in living related and unrelated kidney transplantations after mid-term follow-ups (P = 0.46) (Figure 3).

**Short-term (one year) graft survival rate:** We conducted fixed effect meta-analyses because the results from the studies reporting one year graft survival rate after living related and unrelated renal transplantations showed no significant heterogeneity (P = 0.11). There were no significant differences between the graft survival rate in living related and unrelated kidney transplantations after a one year follow-up (P = 0.35) (Figure 3).

**Acute rejection rate:** We conducted fixed effect meta-analyses because the results from the studies reporting acute rejection rate after living related and unrelated renal transplantations showed no significant heterogeneity (P = 0.17). There were no significant differences between the acute rejection rate in living related and unrelated kidney transplantations (P = 0.06) (Figure 3).

### DISCUSSION

This systematic meta-analysis showed that no significant difference existed in graft survival rate between living related and unrelated kidney transplantations in short, mid and long-term follow-ups.

In comparison to dialysis, transplantation has lengthened the patient's survival and improved their quality of life; in the medical field, it has broadened knowledge; to sponsors, it has provided a cost-effective solution for a never-ending problem. On the other hand, the shortcoming of transplantation is the unavailability of enough donors. This led to scientists using living unrelated kidney transplantations as an available source, but there were strong controversies in this respect. A detailed analysis suggests that the difference was related to a "centre effect". The inferior outcomes of living unrelated-donor transplantations were caused by the low standards of medical care in commercial transplantation programmes, the infections transmitted between the donor organs or patient non-compliance. After correcting these factors<sup>[20,21]</sup>, the reports have shown no significant difference in graft outcomes when compared with living related transplantations. Our results support the finding that showed no significant difference between living related and unrelated kidney graft survival rates after mid-term and short-term follow-ups.

This systematic review and meta-analysis showed that the long-term graft survival rate has not a significant difference between the living related and the living unrelated groups. In our previous report<sup>[5]</sup>, we evaluated the recipients of kidney transplants for 25 years and a comparable survival rate was found between the two groups. Park et al<sup>[12]</sup> reported the graft survival rates at 3, 5 and 10 years as 91.9%, 88.5% and 74.7% for the LURD vs 94%, 84% and 78.8% for the LRD transplants, with no significant difference. In contrast to our findings, previous studies showed no significant difference in long-term graft surveillance between the two groups<sup>[5,9,14]</sup>. This might be because of significant heterogeneity between the studies. As the funnel plot described, there is significant heterogeneity between the studies; therefore, in the future, more studies with a high quality of methodology are warranted.

While unrelated kidney transplantations are not widely accepted, the concern for transplantations continues to revolve around the issue of inadequate material benefits for potential donors<sup>[22]</sup>. The only model that resolved this issue was the model used in Iran. This model is organized by a non-profit organization known as the "Dialysis and Transplant Patients' Association (DATPA)"<sup>[23]</sup>. The DATPA's task is to assign appropriate donors for certain recipients and to offer medicolegal coverage. Donors receive a form of compensation from the government and the DATPA, and in addition, they are granted free life-long health insurance, and often, a "rewarding gift from the recipient"<sup>[23]</sup>. This model has been very successful over the past two decades in Iran, nearly eradicating the names on the transplant waiting list and gracefully providing a second chance at life for patients with ESRD; this model comprises over 75% of the total kidney transplant activity in Iran.

As a limitation, because of the lack of data, we could not evaluate the difference in HLA mismatches between the studies. Nevertheless, previous studies have reported equivalent short-, medium- and long-term outcomes of transplantation in LURD series in comparison to LRDs.



### Simforoosh N et al. Living related vs unrelated kidney transplantation

n years graft survival ra	-		iving unre			Risk ratio			Risk ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95%CI	Year		M-H, Random, 95%CI	
Cortesini 2002	199	302	118	172	17.1%	0.96 [0.84, 1.09]	2002		<b>e</b> -	
Park 2004	28	36	30	41	13.4%	1.06 [0.82, 1.37]	2004			
Simforoosh 2006	241	374	1200	1760	18.2%	0.95 [0.87, 1.03]	2006		9	
Santori 2012	71	111	21	24	14.9%	0.73 [0.60, 0.90]	2012		-8-	
Simforoosh 2015	225	411	2350	3305	18.0%	0.77 [0.70, 0.84]	2015		8	
Matter 2016	1660	2075	270	410	18.4%	1.21 [1.13, 1.31]	2016			
Total (95%CI)		3309		5712	100.0%	0.94 [0.79, 1.11]			•	
Toatl events	2424	70.00	3989		1) 7 <sup>2</sup> 01	201		I		
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:				< 0.0000	(1); T = 9.	3%		0.01	0.1 1 10 Living related Living unrelated	100
e years graft survival ra	ate Living	g related	Living un	related		Risk ratio			Risk ratio	
Study or subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95%C	I Yea		M-H, Random, 95%CI	
Cortesini 2002	232	302	136	172	13.4%	0.97 [0.88, 1.07]	2002	2	<b>a</b> +	
Kizilisik 2004	75	85	21	24	8.4%	1.01 [0.85, 1.20]	2004	1		
Park 2004	30	36	36	41	7.5%	0.95 [0.79, 1.14]	2004	1		
Wolters 2005	62	66	23	29	7.1%	1.18 [0.97, 1.44]	200		-	
Simforoosh 2006	286	374	1432	1760	16.6%	0.94 [0.88, 1.00]	2000		a	
Simforoosh 2015	288	411	2697	3305	16.2%	0.86 [0.80, 0.92]	201			
Ali 2016	80	92	125	143	13.2%	0.99 [0.90, 1.10]	2010			
Matter 2016	1784	2075	340	410	17.6%	1.04 [0.99, 1.09]	2010		e e	
Total (95%CI)		3441		5884	100.0%	0.98 [0.91, 1.04]				
Toatl events	2837	J-11	4810	5004	100.070	0.50 [0.51/ 1.01]				
Heterogeneity: Tau <sup>2</sup> =		= 28.14.		= 0.0002	$P$ ): $I^2 = 75$	%				
	<i>,</i> x				-,,			<b>0.01</b>	0.1 1 10	10
Test for overall effect:	Z = 0.74	+ ( <i>P</i> = 0.46	o)						المصاحبا مستنبذا المصاحبا مستنبذا	
Test for overall effect:	<i>Z</i> = 0.74	+ ( <i>P</i> = 0.46	)						Living related Living unrelated	
Test for overall effect: ne year graft survival rat				elated		Risk ratio			Living related Living unrelated Risk ratio	
				elated Total	Weight	Risk ratio M-H, Fixed, 95%CI	Year			
e year graft survival rat	te Living	related I	_iving unr		Weight 8.0%		Year 2002		Risk ratio	
e year graft survival rat Study or subgroup	te Living Events	related I Total	_iving unn Events	Total	-	M-H, Fixed, 95%CI			Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002	te Living Events 275	related I Total 302	Living unre Events	Total 172	8.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12]	2002		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003	te Living Events 275 36	related I Total 302 38	Living unn Events 150 24	Total 172 24	8.0% 1.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05]	2002 2003		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006	te Living Events 275 36 81	related I Total 302 38 85	Living unn Events 150 24 23 1610	Total 172 24 24	8.0% 1.3% 1.5%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09]	2002 2003 2004 2006		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008	te Living Events 275 36 81 342 247	related 1 Total 302 38 85 374 261	Living unn Events 150 24 23 1610 60	Total 172 24 24 1760 61	8.0% 1.3% 1.5% 23.7%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00]	2002 2003 2004 2006 2008		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012	te Living Events 275 36 81 342 247 65	related 1 Total 302 38 85 374 261 66	Living unre Events 150 24 23 1610 60 43	Total 172 24 24 1760 61 44	8.0% 1.3% 1.5% 23.7% 4.1% 2.2%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06]	2002 2003 2004 2006 2008 2012		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015	te Living Events 275 36 81 342 247 65 366	related 1 Total 302 38 85 374 261 66 411	Living unr Events 150 24 23 1610 60 43 2974	Total 172 24 24 1760 61 44 3305	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03]	2002 2003 2004 2006 2008 2012 2015		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012	te Living Events 275 36 81 342 247 65	related 1 Total 302 38 85 374 261 66	Living unre Events 150 24 23 1610 60 43	Total 172 24 24 1760 61 44	8.0% 1.3% 1.5% 23.7% 4.1% 2.2%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06]	2002 2003 2004 2006 2008 2012		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016	te Living Events 275 36 81 342 247 65 366 2012	related 1 Total 302 38 85 374 261 66 411 2075	Living unn Events 150 24 23 1610 60 43 2974 389	Total 172 24 24 1760 61 44 3305 410 143	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.6% 27.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13]	2002 2003 2004 2006 2008 2012 2015 2016		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events	te Living Events 275 366 81 342 247 65 366 2012 90 3514	related 1 Total 302 38 85 374 261 66 411 2075 92 3704	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404	Total 172 24 1760 61 44 3305 410 143 5943	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.6% 27.3% 4.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05]	2002 2003 2004 2006 2008 2012 2015 2016		Risk ratio	
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI)	te Living Events 275 366 81 342 247 65 366 2012 90 3514	related 1 Total 302 38 85 374 261 66 411 2075 92 3704	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404	Total 172 24 1760 61 44 3305 410 143 5943	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.6% 27.3% 4.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13]	2002 2003 2004 2006 2008 2012 2015 2016 2016		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events	te Living Events 275 366 247 65 366 2012 90 3514 12.99, df	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( <i>P</i> = 1	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); <i>I</i> <sup>2</sup> =	Total 172 24 1760 61 44 3305 410 143 5943	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.6% 27.3% 4.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13]	2002 2003 2004 2006 2008 2012 2015 2016 2016	0.01	Risk ratio	100
he year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect:	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0$ 8 ( $P = 0.32$	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); <i>1</i> <sup>2</sup> =	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38%	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13]	2002 2003 2004 2006 2008 2012 2015 2016 2016		Risk ratio M-H, Random, 95%CI	100
te year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0$ 8 ( $P = 0.3$ ) ng related	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); <i>1</i> <sup>2</sup> =	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38%	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02]	2002 2003 2004 2006 2008 2012 2015 2016 2016		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0$ 8 ( $P = 0.32$ ) ng related	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); <i>1</i> <sup>2</sup> =	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38%	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI	2002 2003 2004 2006 2008 2012 2015 2016 2016		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup	te Living Events 275 366 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livii Events	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0.3$ ) and ( $P$	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $I^2 =$ 5) Living Events	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38%	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio Kisk ratio 0.97 [0.60, 1.56]	2002 2003 2004 2006 2012 2015 2016 2016		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Total (95%CI) Total vents Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin Events 20 11	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0.3$ ) and related Total 38 3704	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $T^2 =$ Living Events 13 13	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0% 100.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio Kisk ratio 0.97 [0.60, 1.56]	2002 2003 2004 2008 2012 2015 2016 2016 2016 Year 2003 2004		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin Events 20 11 11	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0$ 8 ( $P = 0.32$ in grelated Total 38 36 85	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $I^2 =$ 5) Living Events 13 13 5	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24 41 24 24 24 24 24 24 24 24 24 24	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0% 100.0%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88]	2002 2003 2004 2008 2012 2015 2016 2016 2016 Year 2003 2004 2004		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livii Events 20 11 11 6	related I Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 1$ 8 ( $P = 0$ 8 ( $P = 0$ 8 ( $P = 0$ 8 ( $P = 0$ 38 37 4 5 6 6 6 6 6 6 6 6 7 7 8 7 8 8 8 6 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $T^2 =$ 5) Living Events 13 13 13 5 5	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24 41 24 24 24 24 25 24 24 24 24 24 24 24 24 24 24	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.3% 4.3% 100.0% 100.0% ed Weight 11.6% 8.9% 5.7% 5.1%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59]	2002 2003 2004 2008 2012 2015 2016 2016 2016 2016 2016 2016 2004 2004 2004		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005 Nadeem 2008	te Living Events 275 366 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin Events 20 11 11 6 107	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 1$ 8 ( $P = 0.32$ in grelated 38 36 85 66 261	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $T^2 =$ 5) Living Events 13 13 55 21	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.3% 4.3% 100.0% 100.0% 100.0% 8.9% 5.7% 5.1% 24.8%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59] 1.19 [0.82, 1.73]	2002 2003 2004 2008 2012 2016 2016 2016 2016 2016 2003 2004 2003 2004 2005 2008		Risk ratio M-H, Random, 95%CI	100
e year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livii Events 20 11 11 6	related I Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 1$ 8 ( $P = 0$ 8 ( $P = 0$ 8 ( $P = 0$ 8 ( $P = 0$ 38 37 4 5 6 6 6 6 6 6 6 6 7 7 8 7 8 8 8 6 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $T^2 =$ 5) Living Events 13 13 13 5 5	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24 41 24 24 24 24 25 24 24 24 24 24 24 24 24 24 24	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.3% 4.3% 100.0% 100.0% ed Weight 11.6% 8.9% 5.7% 5.1%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59]	2002 2003 2004 2008 2012 2015 2016 2016 2016 2016 2016 2016 2004 2004 2004		Risk ratio M-H, Random, 95%CI	100
he year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Total events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005 Nadeem 2008 Ishikawa 2012 Matter 2016 Total (95%CI)	te Living Events 275 366 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livii Events 20 11 11 6 107 16 71	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 1$ 8 ( $P = 0.3$ ) mg related Total 38 36 85 66 261 74 2075 92 3704 261 275 261 275 275 275 275 275 275 275 275	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $I^2$ = 5) Living Events 13 13 5 5 21 14 26	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Total 24 41 24 41 24 41 24 41 24 42 61 43 5943 44 24 24 44 29 61 44 43 5943 44 44 44 43 5943 44 44 44 44 44 44 44 44 44	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0% 100.0% 100.0% 100.0% 100.0% 11.6% 8.9% 5.7% 5.1% 24.8% 12.3% 31.7%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59] 1.19 [0.82, 1.73] 0.76 [0.42, 1.40]	2002 2003 2004 2008 2012 2015 2016 2016 2016 2016 2003 2004 2004 2004 2005 2008 2012		Risk ratio M-H, Random, 95%CI	100
he year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Toatl events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005 Nadeem 2008 Ishikawa 2012 Matter 2016 Total (95%CI) Toatl events	te Living Events 275 36 81 342 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin Events 20 11 11 6 107 16 71 242	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0.3$ ) arrotal 38 36 85 66 2075 2627	Living unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $J^2 =$ Events 13 13 5 5 21 14 26 97	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24 41 24 29 61 44 124 29 61 44 305 543 24 41 61 61 61 61 61 61 61 61 61 6	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0% 100.0% 100.0% 100.0% 100.0% 11.6% 8.9% 5.7% 5.1% 24.8% 12.3% 31.7%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59] 1.19 [0.82, 1.73] 0.76 [0.42, 1.40] 0.54 [0.35, 0.83]	2002 2003 2004 2008 2012 2015 2016 2016 2016 2016 2003 2004 2004 2004 2005 2008 2012	0.01	Risk ratio M-H, Random, 95%CI	
he year graft survival rat Study or subgroup Cortesini 2002 Voiculescu 2003 Kizilisik 2004 Simforoosh 2006 Nadeem 2008 Ishikawa 2012 Simforoosh 2015 Matter 2016 Ali 2016 Total (95%CI) Total events Heterogeneity: $\chi^2 = 1$ Test for overall effect: Acute rejection rate Study or subgroup Voiculescu 2003 Park 2004 Kizilisik 2004 Wolters 2005 Nadeem 2008 Ishikawa 2012 Matter 2016 Total (95%CI)	te Living Events 275 366 247 65 366 2012 90 3514 12.99, df Z = 0.93 Livin Events 20 11 11 6 107 16 71 242 0.03, df =	related 1 Total 302 38 85 374 261 66 411 2075 92 3704 = 8 ( $P = 0.3$ ) arrotal 38 36 85 66 2075 2627 6 ( $P = 0.3$ )	iving unn Events 150 24 23 1610 60 43 2974 389 131 5404 0.11); $I^2$ = 13 Events 5 5 13 13 13 5 5 5 21 14 26 97 17); $I^2$ =	Total 172 24 24 1760 61 44 3305 410 143 5943 = 38% g unrelate Tota 24 41 24 29 61 44 124 29 61 44 305 543 24 41 61 61 61 61 61 61 61 61 61 6	8.0% 1.3% 1.5% 23.7% 4.1% 2.2% 27.6% 27.3% 4.3% 100.0% 100.0% 100.0% 100.0% 100.0% 11.6% 8.9% 5.7% 5.1% 24.8% 12.3% 31.7%	M-H, Fixed, 95%CI 1.04 [0.98, 1.12] 1.95 [0.86, 1.05] 0.99 [0.90, 1.09] 1.00 [0.97, 1.03] 0.96 [0.92, 1.00] 1.01 [0.95, 1.06] 0.99 [0.95, 1.03] 1.02 [1.00, 1.05] 1.07 [1.01, 1.13] 1.01 [0.99, 1.02] Risk ratio M-H, Fixed, 95%CI 0.97 [0.60, 1.56] 0.96 [0.49, 1.88] 1.62 [0.24, 1.61] 1.53 [0.17, 1.59] 1.19 [0.82, 1.73] 0.76 [0.42, 1.40] 0.54 [0.35, 0.83]	2002 2003 2004 2008 2012 2015 2016 2016 2016 2016 2003 2004 2004 2004 2005 2008 2012		Risk ratio M-H, Random, 95%CI	100

Figure 3 Comparing long, mid and short term graft survival rate and acute rejection rate between living related and unrelated kidney transplantations.

In conclusion, the long, mid and short-term followup of living related and unrelated kidney transplantation showed no significant difference in graft survival rate. Also, acute rejection rate was not significantly different between groups. We suggest that the Iranian model is a fair compromise because it avoids the rampant

### transplant commercialism.

### COMMENTS

### Background

The number of patients who are on the renal transplant waiting list for deceased-

159

donor transplantation has increased and thousands of patients have died while waiting for renal transplantation. Despite this, no systematic review and metaanalysis has been performed yet.

### **Research frontiers**

Nowadays the outcomes of living related vs unrelated kidney transplantation are debatable. Worldwide research is directed towards the use of living unrelated kidney transplantation as a potential source.

### Innovations and breakthroughs

In the present study, the authors investigated the outcomes of two kinds of sources in kidney transplantation by pooling results from different centres. This is the first report of a meta-analysis comparing these sources in receipts.

### Applications

The present report provides an understanding of living unrelated kidney transplantation as an excellent source.

### Peer-review

In this manuscript authors performed a meta-analysis to compare related and unrelated living donor kidney transplant outcome. Results indicate comparable outcome of kidney transplant from living unrelated vs related donors in the short, mid and long term follow up.

### REFERENCES

- Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. *Nephrol Dial Transplant* 2002; 17: 2071-2076 [PMID: 12454213 DOI: 10.1093/ndt/17.12.2071]
- 2 Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. *J Am Soc Nephrol* 1998; 9: 2135-2141 [PMID: 9808102]
- 3 Sesso R, Josephson MA, Anção MS, Draibe SA, Sigulem D. A retrospective study of kidney transplant recipients from living unrelated donors. *J Am Soc Nephrol* 1998; 9: 684-691 [PMID: 9580370]
- 4 Ghods AJ. Renal transplantation in Iran. *Nephrol Dial Transplant* 2002; **17**: 222-228 [PMID: 11812870 DOI: 10.1093/ndt/17.2.222]
- 5 Simforoosh N, Basiri A, Tabibi A, Javanmard B, Kashi AH, Soltani MH, Obeid K. Living Unrelated Versus Related Kidney Transplantation: A 25-Year Experience with 3716 Cases. Urol J 2016; 13: 2546-2551 [PMID: 26945660]
- 6 Barsoum RS. The Egyptian transplant experience. *Transplant Proc* 1992; 24: 2417-2420 [PMID: 1465813]
- 7 Sever MS, Kazancioğlu R, Yildiz A, Türkmen A, Ecder T, Kayacan SM, Celik V, Sahin S, Aydin AE, Eldegez U, Ark E. Outcome of living unrelated (commercial) renal transplantation. *Kidney Int* 2001; 60: 1477-1483 [PMID: 11576362 DOI: 10.1046/ j.1523-1755.2001.00951.x]
- 8 Jha V, Chugh KS. The case against a regulated system of living kidney sales. *Nat Clin Pract Nephrol* 2006; 2: 466-467 [PMID: 16941033 DOI: 10.1038/ncpneph0268]
- 9 Cortesini R, Pretagostini R, Bruzzone P, Alfani D. Living unrelated kidney transplantation. *World J Surg* 2002; 26: 238-242 [PMID: 11865354 DOI: 10.1007/s00268-001-0211-4]
- 10 Voiculescu A, Ivens K, Hetzel GR, Hollenbeck M, Sandmann

W, Grabitz K, Balzer K, Schneider F, Grabensee B. Kidney transplantation from related and unrelated living donors in a single German centre. *Nephrol Dial Transplant* 2003; **18**: 418-425 [PMID: 12543901]

- 11 Kizilisik AT, Ray JM, Nylander WA, Langone AJ, Helderman JH, Shaffer D. Living donor kidney transplantation in a Veterans Administration medical center. *Am J Surg* 2004; **188**: 611-613 [PMID: 15546581 DOI: 10.1016/j.amjsurg.2004.07.022]
- 12 Park YH, Min SK, Lee JN, Lee HH, Jung WK, Lee JS, Lee JH, Lee YD. Risk factors on graft survival of living donor kidney transplantation. *Transplant Proc* 2004; 36: 2023-2025 [PMID: 15518732 DOI: 10.1016/j.transproceed.2004.09.009]
- Wolters HH, Heidenreich S, Dame C, Brockmann JG, Senninger N, Krieglstein CF. Living donor kidney transplantation: impact of differentiated immunosuppressive regimen. *Transplant Proc* 2005; 37: 1616-1617 [PMID: 15866688 DOI: 10.1016/j.transproceed.200 4.09.022]
- 14 Simforoosh N, Basiri A, Fattahi MR, Einollahi B, Firouzan A, Pour-Reza-Gholi F, Nafar M, Farrokhi F. Living unrelated versus living related kidney transplantation: 20 years' experience with 2155 cases. *Transplant Proc* 2006; **38**: 422-425 [PMID: 16549137 DOI: 10.1016/j.transproceed.2006.01.012]
- 15 Ahmad N, Ahmed K, Khan MS, Calder F, Mamode N, Taylor J, Koffman G. Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation? *Ann R Coll Surg Engl* 2008; **90**: 247-250 [PMID: 18430342 DOI: 10.1308/00358840 8X261636]
- 16 Ishikawa N, Yagisawa T, Kimura T, Sakuma Y, Fujiwara T, Nukui A, Yashi M. Kidney transplantation of living unrelated and ABO-incompatible donor-recipient combinations. *Transplant Proc* 2013; 45: 1242-1244 [PMID: 23622668 DOI: 10.1016/j.transproceed.201 3.02.028]
- 17 Santori G, Barocci S, Fontana I, Bertocchi M, Tagliamacco A, Biticchi R, Valente U, Nocera A. Kidney transplantation from living donors genetically related or unrelated to the recipients: a singlecenter analysis. *Transplant Proc* 2012; 44: 1892-1896 [PMID: 22974864 DOI: 10.1016/j.transproceed.2012.05.061]
- 18 Matter YE, Nagib AM, Lotfy OE, Alsayed AM, Donia AF, Refaie AF, Akl AI, Abbas MH, Abuelmagd MM, Shaeashaa HA, Shokeir AA. Impact of Donor Source on the Outcome of Live Donor Kidney Transplantation: A Single Center Experience. *Nephrourol Mon* 2016; 8: e34770 [PMID: 27570751 DOI: 10.5812/ numonthly.34770]
- 19 Ali AA, Al-Saedi AJ, Al-Mudhaffer AJ, Al-Taee KH. Five years renal transplantation data: Single-center experience from Iraq. *Saudi J Kidney Dis Transpl* 2016; 27: 341-347 [PMID: 26997389 DOI: 10.4103/1319-2442.178559]
- 20 Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med* 1995; 333: 333-336 [PMID: 7609748 DOI: 10.1056/NEJM199508103330601]
- 21 Gheith O, Sabry A, El-Baset SA, Hassan N, Sheashaa H, Bahgat S, El-Shahawy el-M. Study of the effect of donor source on graft and patient survival in pediatric renal transplant recipients. *Pediatr Nephrol* 2008; 23: 2075-2079 [PMID: 18446383 DOI: 10.1007/s00467-008-0760-y]
- 22 Delmonico FL. The development of the Declaration of Istanbul on Organ Trafficking and Transplant Tourism. *Nephrol Dial Transplant* 2008; 23: 3381-3382 [PMID: 18922862 DOI: 10.1093/ndt/gfn552]
- 23 Ghods AJ, Savaj S. Iranian model of paid and regulated livingunrelated kidney donation. *Clin J Am Soc Nephrol* 2006; 1: 1136-1145 [PMID: 17699338 DOI: 10.2215/CJN.00700206]

P- Reviewer: Friedman EA, Gheith O, Piancatelli D, Shrestha BM S- Editor: Ji FF L- Editor: A E- Editor: Wu HL





WJT www.wjgnet.com



# Published by Baishideng Publishing Group Inc

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.f6publishing.com

